Read + Share
Svenningsson P, Odin P, Bergquist F, Wirdefeldt K, et al. NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and
Anti-Parkinsonian Efficacy. Mov Disord 2025 Mar 17. doi: 10.1002/mds.30175.
PMID: 40091754
|
 |
|
Svenningsson P, Odin P, Bergquist F, Wirdefeldt K, et al. NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and
Anti-Parkinsonian Efficacy. Mov Disord 2025 Mar 17. doi: 10.1002/mds.30175.
PMID: 40091754
|
|
|
|